Kedrab Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high rabies fatality rates, reliance on immunoglobulin products, limited early vaccine access, public health emergency protocols, hospital based rabies management.

The growth in the forecast period can be attributed to increasing animal bite incidents, expansion of rabies awareness campaigns, growth in emergency care infrastructure, improved access to monoclonal antibodies, rising government investment in rabies prevention. Major trends in the forecast period include growing use of rabies passive immunization, expansion of post exposure prophylaxis programs, rising focus on zoonotic disease control, increased emergency immunotherapy demand, strengthening public health response systems.

The increasing incidence of rabies is expected to drive the Kedrab market in the future. Rabies is a nearly always fatal disease caused by exposure to rabid animals, making it a critical public health concern, especially in regions with limited access to vaccines. The rise in rabies cases is primarily driven by inadequate vaccination of domestic animals, limited access to post-exposure prophylaxis (PEP), and the prevalence of rabies in wildlife, particularly in underserved areas. Kedrab, a human rabies immunoglobulin, provides immediate passive immunity to individuals exposed to the rabies virus, offering crucial protection until active immunity develops through vaccination. For example, in April 2024, the South Dakota Department of Health reported that around 20 animals in South Dakota were confirmed to have rabies in 2023, a 122% increase from the 9 cases in 2022. As a result, the growing incidence of rabies is driving the demand for Kedrab.

Major companies are actively operating in the Kedrab market, focusing on developing innovative solutions and securing regulatory agreements like exclusive licensing and distribution continuation notices to expand Kedrab's commercial reach, particularly in the U.S. An exclusive licensing and distribution continuation notice is an official communication from a pharmaceutical or biotechnology company announcing the extension or renewal of an agreement granting exclusive rights to license, distribute, or commercialize a specific product. For instance, in July 2023, Kamada Ltd., an Israel-based plasma-derived biopharmaceutical company, announced that Kedrion Biopharma exercised its option to extend the exclusive U.S. distribution agreement for KEDRAB. This two-year extension ensures continued availability and supply stability, supporting Kedrion’s commercial distribution infrastructure and strategic presence in the U.S. immunoglobulin market, which enhances patient access and public health preparedness.

In December 2023, Kedrion Biopharma, an Italy-based biopharmaceutical company, partnered with Kamada to further strengthen their distribution agreement for KEDRAB. This collaboration underscores Kedrion's ongoing commitment to providing critical therapies derived from hyperimmune plasma and its strategic focus on expanding its market presence to combat rabies and other critical diseases. Kamada Ltd. is an Israel-based biopharmaceutical company.

Major companies operating in the kedrab market are Kamada Ltd., Kedrion Biopharma Inc.

North America was the largest region in the kedrab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kedrab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kedrab market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the kedrab market by increasing costs related to antibody production, sterile injectables, and international distribution logistics. These effects are most visible in hospital and emergency department channels, especially in regions dependent on imported rabies biologics. Higher tariffs may limit affordability and timely access in high risk exposure settings. At the same time, tariffs are promoting local antibody manufacturing, technology transfer initiatives, and stronger regional supply chains to support sustained rabies prevention efforts.

The kedrab market research report is one of a series of new reports that provides kedrab market statistics, including kedrab industry global market size, regional shares, competitors with a kedrab market share, detailed kedrab market segments, market trends and opportunities, and any further data you may need to thrive in the kedrab industry. This kedrab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Kedrab is a monoclonal antibody used for the prevention and treatment of rabies following potential exposure to the virus. Derived from human sources, it provides passive immunity by neutralizing the rabies virus, helping to prevent the onset of disease when administered after exposure.

The primary indications for Kedrab are post-exposure prophylaxis (PEP) for rabies and treatment for patients exposed to suspected rabid animals. PEP for rabies involves immediate wound cleansing, the administration of rabies immunoglobulin, and a series of rabies vaccinations to prevent the progression of the virus after exposure. Kedrab is available in injectable formulations and lyophilized powders for reconstitution, with routes of administration including intramuscular injection and subcutaneous injection. The product is distributed through direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies. It is utilized by various end users, including hospitals, emergency departments, specialty clinics, and public health organizations.

The kedrab market consists of sales of kedrab-related biopharmaceutical products, including plasma-derived therapies and other related treatments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.